Ultrapure factor VIIi concentrate with double virus inactivation: study of pharmacokinetics in von Willebrand's disease patients
Canales Albendea, M.A.; Villar Camacho, A.; Chamarro Merino, G.; Magallón Martínez, M.
Sangre 43(1): 93-94
1998
ISSN/ISBN: 0036-4355 PMID: 9577189 Document Number: 488376
Document emailed within 1 workday
Related Documents
Van Vliet, H.H.D.M.; Kappers-Klunne, M.C.; Leebeek, F.W.G.; Michiels, J.J. 2008: PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2 Thrombosis and Haemostasis 100(3): 462-468Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Mazurier, C.; Meyer, D. 1996: Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease--results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH Thrombosis and Haemostasis 76(2): 270-274
Arrighi, S.; Rossi, R.; Borri, M.G.; Lesnikov, V.; Lesnikova, M.; Franco, E.; Divizia, M.; De Santis, M.E.; Bucci, E. 1995: "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate Thrombosis and Haemostasis 74(3): 868-873
Escolar, G.; Carretero, M.; Magallón, M.; Quintana, M.; Arnau, C.; Castillo, R.; Aznar-Salatti, J. 1998: von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease Haematologica 83(11): 1009-1014
Girma, J.P.; Pietu, G.; Lavergne, J.M.; Meyer, D.; Larrieu, M.J. 1982: Abnormal antigenic reactivity of factor VIII/von Willebrand factor subunit in variants of von Willebrand's disease Journal of Laboratory and Clinical Medicine 99(4): 481-494
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Sultan, Y.; Simeon, J.; Caen, J.P. 1976: Electrophoretic heterogeneity of normal factor VIII/Von Willebrand protein, and abnormal electrophoretic mobility in patients with Von Willebrand's disease Journal of Laboratory and Clinical Medicine 87(2): 185-194
Meyer, D.; Obert, B.; Pietu, G.; Lavergne, J.M.; Zimmerman, T.S. 1980: Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease Journal of Laboratory and Clinical Medicine 95(4): 590-602
Mannucci, P.M.; Zanetti, A.R.; Colombo, M.; Chistolini, A.; De Biasi, R.; Musso, R.; Tamponi, G. 1990: Antibody to hepatitis C virus after a vapour-heated factor VIIi concentrate. the Study Group of the Fondazione dell'Emofilia Thrombosis and Haemostasis 64(2): 232-234
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Takahashi, H. 1981: Studies on the pathophysiology and treatment of von Willebrand's disease. II. Gel filtration studies on plasma factor VIIi in von Willebrand's disease Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 44(1): 165-172
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Takase, T.; Nishino, M.; Yasui, M.; Shima, M.; Yoshikawa, N.; Fukui, H. 1985: Multimeric composition of factor VIII-related protein following DDAVP infusion in normal subjects and patients with hemophilia a and von Willebrand's disease Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 48(7): 1571-1578
Kessler, C.; Lusher, J.; Pierce, G.F.; Pierce, B.; Koerper, M.A.; Dickinson, J.C. 1995: Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIIi concentrate Lancet 346(8985): 1297-1298
Bolland, J.; Lambotte, C. 1978: Factor VIIi in hemophilia and von Willebrand's disease Revue Medicale de Liege 33(8): 284-295
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Kunst, V.A.; Nováková, I.R.; Haanen, C. 1989: Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A Nederlands Tijdschrift Voor Geneeskunde 133(23): 1163-1166